Skip to main content
SpringerLink
Log in
Book cover

Intensive Care Medicine pp 129–135Cite as

Endogenous Anticoagulants and the Role of Heparin in the Treatment of Severe Sepsis

  • Conference paper

  • 328 Accesses

Abstract

New treatments for severe sepsis have yielded disappointing results in numerous trials conducted in the past 20 years. The interventions tested improved survival only marginally, if at all. Some were associated with unexpected toxicities. Not a single new agent had been introduced into clinical practice until recently [1–4].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Graf J, Doig GS, Cook DJ, Vincent JL, Sibbald WJ (2002) Randomized, controlled clinical trials in sepsis: has methodological quality improved over time? Crit Care Med 30: 461 - 472

    Article  PubMed  Google Scholar 

  2. Marshall JC (2000) Clinical trials of mediator-directed therapy in sepsis: what have we learned? Intensive Care Med 26 (suppl 1): S75 - S83

    Article  PubMed  Google Scholar 

  3. Natanson C, Esposito CJ, Banks SM (1998) The sirens’ songs of confirmatory sepsis trials: selection bias and sampling error. Crit Care Med 26: 1927 - 1931

    Article  PubMed  CAS  Google Scholar 

  4. Opal SM, Cross AS (1999) Clinical trials for severe sepsis. Past failures, and future hopes. Infect Dis Clin North Am 13: 285-297

    Google Scholar 

  5. Bernard GR, Vincent JL, Laterre PF, et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699 - 709

    Article  PubMed  CAS  Google Scholar 

  6. Angus DC, Laterre P-F, Helterbrand J, Ball D, Garg R, Bernard G (2002) The effects of drotrecogin alfa (activated) on long-term survival after sepsis. Annual Meeting of the American College of Chest Physicians, November 2-7, 2002, San Diego, CA, Abstract 5144

    Google Scholar 

  7. Bernard GR, Macias WL, Vincent J-L (2002) Drotrecogin alfa (activated) cumulative safety update. Annual Meeting of the American College of Chest Physicians, November 2-7, 2002, San Diego, CA, Abstract 5141

    Google Scholar 

  8. Bernard GR, Ely EW, Wright TJ, et al (2001) Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 29: 2051 - 2059

    Article  PubMed  CAS  Google Scholar 

  9. Warren HS, Suffredini AF, Eichacker PQ, Munford RS (2002) Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 347: 1027 - 1030

    Article  PubMed  Google Scholar 

  10. Anti-Infective Advisory Committee. FDA briefing document: drotrecogin alfa (activated) [recombinant human activated protein C (rhAPC)] Xigris. BLA #125029/0. Rockville, Md.: Food and Drug Administration, September 12, 2001. (Accessed November 30, 2002, at http://www.fda.gov/ohrms/dockets/ac/01 /briefing/3797b 1_02_FDAbriefing.pdf

    Google Scholar 

  11. Bernard GR, Margolis B, Shanies H, et al (2002) Efficacy and safety of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis: Report from a single-arm open-label trial in the United States. Annual Meeting of the American College of Chest Physicians, November 2-7, 2002, San Diego, CA, Abstract S142

    Google Scholar 

  12. Warren BL, Eid A, Singer P, et al (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286: 1869 - 1878

    Article  PubMed  CAS  Google Scholar 

  13. Rublee D, Opal SM, Schramm W, Keinecke HO, Knaub S (2002) Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial. Crit Care 6: 349 - 356

    Article  PubMed  Google Scholar 

  14. Vervloet NG, Thijs LG, Hack CE (1998) Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemostas 24: 33 - 34

    Article  CAS  Google Scholar 

  15. Levi M, ten Cate H (1999) Disseminated intravascular coagulation. N Engl J Med 341: 586592

    Google Scholar 

  16. Bock SC, Harris JF, Balazs I, et al (1985) Assignment of the human antithrombin III structural gene to chromosome lq 23-25. Cytogenet Cell Genet 39: 67 - 74

    Article  PubMed  CAS  Google Scholar 

  17. Opal SM, Kessler CM, Roemisch J, Knaub S (2002) Antithrombin, heparin, and heparan sulfate. Crit Care Med 30 (suppl): S325 - S331

    Article  PubMed  CAS  Google Scholar 

  18. Wiedermann CJ, Romisch J (2002) The anti-inflammatory actions of antithrombin - a review. Acta Med Austriaca 29: 89 - 92

    Article  PubMed  Google Scholar 

  19. Iba T, Kidokoro A (2002) High-dose antithrombin therapy for sepsis: mechanisms of action. Shock 18: 389 - 394

    Article  PubMed  Google Scholar 

  20. Eisele B, Lamy M, Thijs LG, et al (1998) Anti-thrombin III in patients with severe sepsis: a randomized, placebo-controlled, double-blind, multicenter trial plus a meta-analysis on all randomized-placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 24: 663 - 672

    Article  PubMed  CAS  Google Scholar 

  21. Rivers E, Nguyen B, Haystad S, et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345: 1368 - 1377

    Article  PubMed  CAS  Google Scholar 

  22. Levi M (2001) Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient. J Crit Care 16: 167 - 177

    Article  PubMed  CAS  Google Scholar 

  23. Opal SM (2001) Clinical impact of novel anticoagulation strategies in sepsis. Curr Opin Crit Care 7: 347 - 353

    Article  PubMed  CAS  Google Scholar 

  24. Healy DP (2002) New and emerging therapies for sepsis. Ann Pharmacother 36: 648 - 654

    Article  PubMed  CAS  Google Scholar 

  25. Ahmed T, Gonzalez BJ, Danta I (1999) Prevention of exercise-induced bronchoconstriction by inhaled low-molecular-weight heparin. Am J Respir Crit Care Med 160: 576 - 581

    Article  PubMed  CAS  Google Scholar 

  26. Coalson JJ, Benjamin B, Archer LT, et al (1978) Prolonged shock in the baboon subjected to infusion of E. coli endotoxin. Circ Shock 5: 423 - 437

    CAS  Google Scholar 

  27. Wheeler AP, Bernard GR (1999) Treating patients with severe sepsis. N Engl J Med 340: 207 - 214

    Article  PubMed  CAS  Google Scholar 

  28. Corrigan JJ (1977) Heparin therapy in bacterial septicemia. J Pediatr 91: 695 - 700

    Article  PubMed  Google Scholar 

  29. Schipper HG, Jenkins CSP, Kahl LH, et al (1978) Antithrombin III transfusion in disseminated intravascular coagulation. Lancet 1: 854 - 856

    Article  PubMed  CAS  Google Scholar 

  30. Davidson BL, Geerts WH, Lensing AW (2002) Low-dose heparin for severe sepsis. N Engl J Med 347: 1036 - 1037

    Article  PubMed  Google Scholar 

  31. Langer M, Riccardi F, Piovella F, et al (2002) Use of anticoagulants in patients with sepsis. JAMA 287: 448 - 449

    Article  PubMed  CAS  Google Scholar 

  32. Kaneider NC, Reinisch CM, Dunzendorfer S, Romisch J, Wiedermann CJ (2002) Syndecan4 mediates antithrombin-induced chemotaxis of human peripheral blood lymphocytes and monocytes. J Cell Sci 115: 227 - 236

    PubMed  CAS  Google Scholar 

  33. Hoffmann JN, Vollmar B, Laschke MW, et al (2002) Adverse effect of heparin on anti-thrombin action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb Haemost 88: 242 - 252

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. C. J. Wiedermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Pechlaner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Intensive Care, Erasme Hospital, Free University of Brussels, Route de Lennik 808, B-1070, Brussels, Belgium

    Jean-Louis Vincent MD, PhD, FCCM, FCCP (Head) (Head)

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Wiedermann, C.J., Pechlaner, C. (2003). Endogenous Anticoagulants and the Role of Heparin in the Treatment of Severe Sepsis. In: Vincent, JL. (eds) Intensive Care Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4757-5548-0_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-5548-0_13

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4757-5550-3

  • Online ISBN: 978-1-4757-5548-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation